Kymera Therapeutics — 21 certified H-1B filings (FY2021–FY2026)

5
Filings · FY2025
$160k
Median base · FY2025
Associate Director, Translational Medicine
Top role · 2 all-time
MA
Top state · 21 all-time
FY

Kymera Therapeutics filed 5 certified H-1B LCAs in FY2025 (up 150% from the year before), with a median base salary of $160k and the middle 50% of offers between $130k and $185k. Across all years it has 21 certified filings since FY2021, most often for Associate Director, Translational Medicine in Massachusetts.

How much does Kymera Therapeutics pay H-1B workers?

Certified base salary by fiscal year: each box is the p25–p75 range, the heavy line the median, the whiskers reach p10–p90. $160k median in FY2025. Base pay only — hover a year for its figures.

$50k$100k$150k$200k$250k$300k’21’22’23’24’25’26

How has Kymera Therapeutics's H-1B hiring changed by year?

3 certified filings in FY2021 → 4 in FY2026. The change column is each year against the one before.

Kymera Therapeutics certified H-1B filings and base salary by fiscal year
Fiscal yearFilingsvs prior FYMedian base
FY20264−20%$126k
FY20255+150%$160k
FY20242−50%$110k
FY20234+33%$90k
FY202230%$95k
FY20213—$83k

Which wage levels does Kymera Therapeutics file?

DOL prevailing-wage levels I–IV approximate experience tiers (I = entry, IV = fully competent). 24% of Kymera Therapeutics's filings sit at Level III–IV. A heavy I–II skew reads as entry-level or contractor-style hiring; a heavy IV skew as senior in-house roles — and higher levels earn more lottery entries.

Share of 21 filings with a wage level · all years

14%
62%
19%
  • Level I14.3%3
  • Level II61.9%13
  • Level III19.0%4
  • Level IV4.8%1

What jobs does Kymera Therapeutics sponsor for H-1B?

The most-filed job titles across all years (DOL titles, employer pay-grade codes stripped), with base-salary percentiles.

Kymera Therapeutics most-sponsored H-1B job titles with base-salary percentiles
Job titleFilingsMedian base
Associate Director, Translational Medicine2$170k
Associate Scientist, Platform Biology2$95k
Associate Scientist, Cellular Pharmacology1$113k
Associate Scientist, Computational Biology1$85k
Associate Scientist, Discovery Biology1$126k
Senior Scientist, Proteomics1$140k
Director, Late Stage Formulations Development1$230k
Principal Scientist, Biological Sciences1$160k
Research Associate II, Cellular Assays1$75k
Scientist II, Oncology Biology1$115k

Where does Kymera Therapeutics hire H-1B workers?

Worksite states on the certified filings, all years. Deeper pink = more filings; hover a state for its figures.

2121Certified filings (log scale)
Kymera Therapeutics H-1B worksite states
StateFilingsMedian base
MA21$120k

What has Kymera Therapeutics filed recently?

Every certified LCA on record for Kymera Therapeutics: job title, worksite, prevailing-wage level and the offered base salary.

Kymera Therapeutics recent certified H-1B LCA filings
FYJob titleBase salary
2026Director, Late Stage Formulations Development$230,000
2026Associate Scientist, Cellular Pharmacology$113,000
2026Associate Scientist, Discovery Biology$125,715
2026Senior Director, Pharmacovigilance Operations$280,000
2025Principal Scientist, Biological Sciences$160,000
2025Scientist, Computational Biology$130,000
2025Associate Director, Translational Medicine$190,000
2025Associate Director, Bioanalytical$185,000
2025Scientist, Discovery Biology$120,000
2024Senior Scientist, Proteomics$140,000
2024Associate Scientist, Platform Biology$110,000
2023Senior Scientist, in Vitro Pharmacology$135,000
2023Research Associate II, Cellular Assays$75,000
2023Senior Research Associate, Platform Biology$90,000
2023Associate Director, Translational Medicine$170,000
2022Associate Scientist, Computational Biology$85,000
2022Scientist II, Oncology Biology$115,000
2022Associate Scientist, Platform Biology$95,000
2021Scientist, Proteomics$82,555
2021Scientist, Platform Biology$82,555
2021Scientist, Oncology Biology$105,872

Common questions about Kymera Therapeutics's H-1B filings

How much does Kymera Therapeutics pay H-1B workers?
Kymera Therapeutics's median certified H-1B base salary is $160k (FY2025), from 5 filings. See the full salary distribution and percentiles above.
How many H-1B workers does Kymera Therapeutics sponsor?
Kymera Therapeutics has 21 certified H-1B Labor Condition Applications on record (FY2021–FY2026).
What jobs does Kymera Therapeutics sponsor for H-1B?
Kymera Therapeutics's most-sponsored H-1B roles include Associate Director, Translational Medicine, Associate Scientist, Platform Biology, Associate Scientist, Cellular Pharmacology, Associate Scientist, Computational Biology.
Where does Kymera Therapeutics hire H-1B workers?
Kymera Therapeutics's top H-1B worksite states are MA.
Does a certified LCA mean an H-1B visa was approved?
No. A Labor Condition Application (LCA) is the Department of Labor attestation an employer must have certified before filing an H-1B petition with USCIS. It records the job, worksite and offered wage, but not whether the petition was filed, selected in the lottery, or approved. Filing counts measure intent to sponsor, not headcount.
What salary do these figures show?
The base annual wage offered on the certified LCA, converted to a yearly amount. Bonus, equity, overtime and benefits are not included, so total compensation is typically higher. Figures are medians and percentiles over certified filings; wages above $5,000,000 a year are excluded as data-entry errors.
What do prevailing-wage levels I–IV mean?
The Department of Labor assigns each LCA an OES wage level from I (entry) to IV (fully competent) for the occupation and area. Under the FY2027 wage-weighted H-1B lottery rule, a higher level earns more selection entries, so an employer's level mix is a proxy for how senior its sponsored roles are.

Keep exploring

Browse all sponsors →

Calculate your H-1B lottery odds →orCheck out the insights →

Source: U.S. Department of Labor, Office of Foreign Labor Certification — certified LCA disclosure data through June 2026 (FY2021–FY2026). An LCA is not an approved visa; pay figures are base salary and exclude bonus and equity. Methodology →